Ocular Therapeutix/$OCUL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ticker
$OCUL
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
274
ISIN
US67576A1007
Website
OCUL Metrics
BasicAdvanced
$1.8B
-
-$1.15
1.50
-
Price and volume
Market cap
$1.8B
Beta
1.5
52-week high
$11.26
52-week low
$5.79
Average daily volume
2.8M
Financial strength
Current ratio
10.222
Quick ratio
9.885
Long term debt to equity
27.852
Total debt to equity
28.663
Interest coverage (TTM)
-16.44%
Profitability
EBITDA (TTM)
-201.834
Gross margin (TTM)
-160.40%
Net profit margin (TTM)
-323.09%
Operating margin (TTM)
-344.83%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-27.21%
Return on equity (TTM)
-57.19%
Valuation
Price to revenue (TTM)
31.135
Price to book
6.64
Price to tangible book (TTM)
6.64
Price to free cash flow (TTM)
-12.512
Free cash flow yield (TTM)
-7.99%
Free cash flow per share (TTM)
-88.56%
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
-11.49%
3-year revenue growth (CAGR)
6.51%
10-year revenue growth (CAGR)
48.15%
3-year earnings per share growth (CAGR)
4.20%
10-year earnings per share growth (CAGR)
-4.96%
What the Analysts think about OCUL
Analyst ratings (Buy, Hold, Sell) for Ocular Therapeutix stock.
Bulls say / Bears say
Ocular Therapeutix's proprietary hydrogel technology enables sustained and controlled drug release, positioning the company as a leader in innovative ophthalmic treatments. (gurufocus.com)
The company's strategic shift towards retinal diseases, including wet age-related macular degeneration and diabetic retinopathy, aligns with growing market demand and presents significant growth opportunities. (investing.com)
Recent leadership appointments, including Dr. Pravin U. Dugel as Executive Chairman, bring extensive expertise in retina care, potentially accelerating the development and commercialization of the company's pipeline. (globenewswire.com)
Ocular Therapeutix reported significant losses of $193.5 million in 2024, with an accumulated deficit of $891.1 million, raising concerns about its financial stability. (gurufocus.com)
The company's heavy reliance on the success of a limited number of products, such as DEXTENZA and pipeline candidates like AXPAXLI, exposes it to substantial risk if these products fail to meet market expectations. (gurufocus.com)
Operating in a highly competitive biopharmaceutical industry, Ocular Therapeutix faces challenges from larger companies with more resources, which could impact its market share and profitability. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
OCUL Financial Performance
Revenues and expenses
OCUL Earnings Performance
Company profitability
OCUL News
AllArticlesVideos
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
GlobeNewsWire·2 weeks ago
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
GlobeNewsWire·4 weeks ago
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocular Therapeutix stock?
Ocular Therapeutix (OCUL) has a market cap of $1.8B as of July 11, 2025.
What is the P/E ratio for Ocular Therapeutix stock?
The price to earnings (P/E) ratio for Ocular Therapeutix (OCUL) stock is 0 as of July 11, 2025.
Does Ocular Therapeutix stock pay dividends?
No, Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Ocular Therapeutix dividend payment date?
Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocular Therapeutix?
Ocular Therapeutix (OCUL) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.